The completion of patient treatment in this pivotal Phase 3 trial is a major derisking milestone, but the binary outcome (top-line data) is not due until mid-CY2027. Traders should monitor for any interim data or regulatory updates. The RMAT designation and large addressable market support a bullish view, but the long timeline to data readout introduces uncertainty.
Drug in focus
MESO drug pipeline →rexlemestrocel-L
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3 / Filed BLA
- Time to market
- LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
- Next catalyst
- None dated
What to watchMesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 17 $17.02entry
- T+1 · 3mo ago −2.06%α −1.38% · $16.67
- T+5 · 3mo ago −2.23%α −1.04% · $16.64
- T+20 · 2mo ago −13.40%α −11.42% · $14.74
- T+60 · 7d ago −17.80%α −14.86% · $13.99
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Mesoblast completed patient treatment in the pivotal Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease, randomizing and treating 350 patients. Top-line results are expected in mid-CY2027. The trial has RMAT designation from the FDA, enabling priority review upon BLA filing.
Key Facts
- Completed patient treatment in pivotal Phase 3 trial MSB-DR004 for rexlemestrocel-L in chronic low back pain (CLBP) associated with degenerative disc disease.
- 350 patients randomized and treated with either rexlemestrocel-L or sham injection.
- Primary endpoint is durable pain reduction at 12 months; secondary endpoints include function, quality of life, and opioid cessation.
- Rexlemestrocel-L has FDA Regenerative Medicine Advanced Therapy (RMAT) designation, allowing priority review upon BLA filing.
- Top-line results expected in mid-CY2027 after last patient completes 12-month follow-up.
- CLBP due to degenerative disc disease has a U.S. prevalence of over 7 million people.
- Company claims potential peak year revenue of >US$10 billion with single-digit market penetration.
Financial Impact
Potential peak year revenue >US$10 billion claimed by company for single-digit market penetration in CLBP/DDD indication.
Risk Factors
- Top-line results may fail to meet primary endpoint, leading to significant downside.
- Long timeline to data (mid-CY2027) means no near-term catalyst from this trial.
- Company's peak revenue estimates are forward-looking and unvalidated.
- Manufacturing or regulatory hurdles could delay BLA submission or approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345802 |
Track record
25 reports on MESO
7 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 10 of 14 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
- Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
- Oct 29, 202618d ago 6-K Bullish 6/10 No price data
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
- Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
- Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
- Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
- Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
- Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers